Intercept Pharmaceuticals

    [td_text_with_title custom_title=”Company description”]Intercept Pharmaceuticals, Inc. (Ticker: ICPT) are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing the proprietary bile acid chemistry. The product candidates have the potential to treat orphan and more prevalent diseases for which there currently are limited therapeutic solutions.


    Obeticholic acid

    OCA is a first-in-class lead product candidate that Selectively binds to and activates the farnesoid X receptor (FXR) Regulates liver, intestinal, and kidney function Modulates inflammatory, metabolic, and immune pathways Intercept is developing OCA in primary biliary cirrhosis (PBC) for patients With an inadequate response to standard-of-care therapy Unable to tolerate standard-of-care therapy PBC is a chronic, autoimmune, cholestatic liver disease If [...]
    [td_text_with_title custom_title=”Latest post”]

    Posts not found

    [/td_text_with_title][td_text_with_title custom_title=”From Wikipedia”]

    Coordinates: 40°40′43″N 78°14′35″W / 40.678631°N 78.243038°W / 40.678631; -78.243038

    Intercept Pharmaceuticals
    Public company
    Traded as NASDAQICPT
    Russell 2000 Component
    Industry Biotechnology
    Founded 2002
    Headquarters New York City, New York, United States
    Key people
    Mark Pruzanski
    (President and CEO)
    Jonathan Silverstein
    (Chairman of the Board of Directors)

    Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease (or non-alcoholic steatohepatitis, NASH), cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.


    The company's lead product is obeticholic acid, OCA, also known as 6-ethyl-chenodeoxycholic acid or INT-747, marketed as Ocaliva. OCA is a potent first-in-class farnesoid X receptor (FXR) agonist. As of March 2017, Ocaliva is approved in the US and the EU for use in primary biliary cholangitis. It is in phase III studies for non-alcoholic steatohepatitis (NASH) and phase II studies for primary sclerosing cholangitis.

    Other products in the development pipeline include INT-767, a dual FXR/TGR5 agonist, and INT-777, a TGR5 agonist.

    Initial public offering and stock history

    Intercept trades on the NASDAQ exchange under the ticker symbol ICPT. The initial public offering of the stock on October 16, 2012 was at $15.[1] A follow-on public offering at $33 took place on June 24, 2013.

    On January 9, 2014, the stock skyrocketed from $72.39 to $275.49, or about 280%, after a planned interim analysis by the independent data safety monitoring board showed that Obeticholic acid met the main goal (improvement of liver histology) at the mid-stage in the FLINT trial in NASH, sponsored by NIDDK.[2][3] The stock continued to climb to $497 over the next few days before falling back to around $317 on March 29, 2014, giving a market capitalization of around $6.2 billion.

    In March 2014, the company released the results of the POISE study of Obeticholic acid in PBC, which showed the drug met the trial's primary endpoint of a reduction in serum alkaline phosphatase, a biomarker for the disease.[4] These results were presented at an international liver meeting in April 2014.[5]

    As of 31 December 2014, the company had 136 employees.[6]

    External links